Study pts Treatment PFS OS
Williamson SK et al. [33] 41 Sorafenib 400mg/mq 28 days 4m 9m
Elser C JCO et al. [20] 26 Sorafenib 400 mg/mq d1-2 NR 4,2m
Vokes EE et al. [25] 51 Bevacizumab + erlotinib 3.8m 6.8m
Feinstein T et al. [34] 25 Pem+ Beva NR RR =36% DCR =95%
Gibson M et al. [35] 28 Cetuximab +Beva 2.8m RR =27%8.1m DCR 76%
Savvides P et al. [36] 23 TXT +RT+Beva 78% 89% DCR 74%
Pfister D et al. [37] 42 CDDP+IMRT+Beva 83% 88% DCR100%
Cohen EE et al. [26] 48 Erlotinib + Beva 4.1m 7.1 RR15%
Salama JK et al. [23] 26 Beva +Hydroxyurea +5FU + RT 59% at 2 yr OS= 58% LRC =67% RR= 86%
+Hydroxyurea +5FU +RT 89% at 2 yr OS= 89% LRC 100% RR= 100%
Argiris A et al. [28] 37 Pem +Beva TTP = 5 m median OS= 11.3m ORR= 30%, CRR = 5%, DCR=  86%.
Harari P.M. et al. [41] 10 wCDDP+Beva+RT NR 22.4
Lee N.Y. et al. [38] 44* Beva + CDDP+IMRTà 3x(Beva+CDDP+5FU) 71.7%** 90.9%**
Argiris A. et al. [39] 46 Cetuximab+Beva 2.8m 7.6m DCR=73%
Yao M et al. [29] 30 TXT+RT+Beva biW 3y 61.7% 3y OS=68.2% LRFS= 84.5% DMFS = 80.5%
Yoo DS et al.[27] 29 Beva-erlotinib àRT+ Beva-erlotinib+ CDDP 3y 82% 3y OS 86% 3y LRFS=85% 3y DMFS= 93%
Hainsworth JD et al. [40] 60 Beva-5FU-PTX-CDDP àRT+ Beva-erlotinib+ PTX 3y 71% 3y OS 82%
Table 1: Clinical trials on antiangiogenic therapies.